case_images: PMC7390838_01
case_images: T2-weighted basal sagittal pituitary MRI performed at diagnosis. The red arrow indicates the sellar mass.
case_images: fendo-11-00471-g0001.jpg
case_images: PMC7390838_01_fendo-11-00471-g0001.jpg
case_images: F1
case_images: T2-weighted sequences with an inhomogeneous contrast distribution due to the presence of internal colliquative areas (Figure 1).
case_images: Imaging performed 3 months after surgery. (A,B) Pituitary MRI, T2-weighted basal sagittal and coronal sequences. (C,D) Pituitary MRI, T1- weighted post-gadolinium sagittal and coronal sequences. (E) Whole body fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) showing pathological uptake in sellar region. Red arrows indicate the sellar lesion.
case_images: fendo-11-00471-g0002.jpg
case_images: PMC7390838_01_fendo-11-00471-g0002.jpg
case_images: F2
case_images: No other areas of increased uptake were identified (Figure 2).
case_images: Pituitary MRI performed after combined therapy with dabrafenib and trametinib, showing the complete remission of the pituitary mass. (A,B) T2-weighted basal sagittal and coronal sequences. (C,D) T1- weighted post-gadolinium sagittal and coronal sequences MRI.
case_images: fendo-11-00471-g0003.jpg
case_images: PMC7390838_01_fendo-11-00471-g0003.jpg
case_images: F3
case_images: After 6 months of therapy, a pituitary MRI showed complete remission (CR) of the disease with no evidence of the mass in the sellar region (Figure 3).